key: cord-0837385-3kuixrd2
authors: Gupta, R. K.; Rosenheim, J.; Bell, L. C. K.; Chandran, A.; Guerra-Assuncao, J. A.; Pollara, G.; Whelan, M.; Artico, J.; Joy, G.; Kurdi, H.; Altmann, D. M.; Boyton, R.; Maini, M.; McKnight, A.; Lambourne, J.; Cutino-moguel, T.; Manisty, C.; Treibel, T. A.; Moon, J.; Chain, B.; Noursadeghi, M.; Investigators, The COVIDsortium
title: Blood transcriptional biomarkers of acute viral infection for detection of pre-symptomatic SARS-CoV 2 infection
date: 2021-01-20
journal: nan
DOI: 10.1101/2021.01.18.21250044
sha: ceac5b4097a273453c32122b4a0c93e48a61d5c0
doc_id: 837385
cord_uid: 3kuixrd2

We hypothesised that host-response biomarkers of viral infections may contribute to early identification of SARS-CoV-2 infected individuals, critical to breaking chains of transmission. We identified 20 candidate blood transcriptomic signatures of viral infection by systematic review and evaluated their ability to detect SARS-CoV-2 infection, compared to the gold-standard of virus PCR tests, among a prospective cohort of 400 hospital staff subjected to weekly testing when fit to attend work. The transcriptional signatures had limited overlap, but were mostly co-correlated as components of type 1 interferon responses. We reconstructed each signature score in blood RNA sequencing data from 41 individuals over sequential weeks spanning a first positive SARS-CoV-2 PCR, and after 6 month convalescence. A single blood transcript for IFI27 provided the highest accuracy for discriminating individuals at the time of their first positive viral PCR result from uninfected controls, with area under the receiver operating characteristic curve (AUROC) of 0.95 (95% confidence interval 0.91-0.99), sensitivity 0.84 (0.7-0.93) and specificity 0.95 (0.85-0.98) at a predefined test threshold. The test performed equally well in individuals with and without symptoms, correlated with viral load, and identified incident infections one week before the first positive viral PCR with sensitivity 0.4 (0.17-0.69) and specificity 0.95 (0.85-0.98). Our findings strongly support further urgent evaluation and development of blood IFI27 transcripts as a biomarker for early phase SARS-CoV-2 infection, for screening individuals such as contacts of index cases, in order to facilitate early case isolation and early antiviral treatments as they emerge.

Among all the signatures, the transcript for Interferon Alpha Inducible Protein 27 (IFI27) by itself provided the best 96 discrimination of contemporaneous SARS-CoV-2 infection by nasopharyngeal PCR, compared to uninfected 97 controls, achieving an AUROC of 0.95 (95% confidence interval 0.91-0.99). Using a pre-specified Z2 cut-off based 98 on two standard deviations above the mean of the uninfected control samples, IFI27 had a sensitivity of 0.84 99 (0.70-0.93) and specificity of 0.95 (0.85-0.98). Three other candidate signatures (Sweeney7, Zaas48 and 100 Pennisi2) had statistically equivalent accuracy to IFI27 using paired DeLong tests (Table 2 ). Fig. S3 shows 101 constituent genes for these four best performing signatures; only one of these (Pennisi2) did not include IFI27. 102

Exclusion of participants with contemporaneous case-defining symptoms at the time of SARS-CoV-2 infection 103 (n=9) had no significant impact on the primary analysis (Table S2) . Scores for each of the four best performing 104 signatures were inversely correlated with SARS-CoV-2 RT-PCR cycle thresholds, also independent of symptoms, 105

suggesting that higher viral loads were associated with higher signature scores ( Figure 2B ; Spearman rank 106 correlation coefficients −0.61 to −0.69). 107

Longitudinal expression of the four best performing signatures peaked at the week of first virus PCR-positivity and 108 had normalised at the point of convalescent sampling (Fig. 2) . Importantly, however, measurements in the week 109 preceding the first positive virus PCR were higher than uninfected controls and convalescent samples. AUROCs 110 for discrimination between samples taken in the week prior to first SARS-CoV-2 detection and uninfected controls 111 revealed statistically significant discrimination, but were lower than those for contemporaneous virus PCR positivity 112 (Table S3) . For illustration, IFI27 predicted infection one week before a positive virus PCR test with an AUROC of 113 0.79 (0.6-0.98). At a Z2 cut-off this achieved sensitivity of 0.4 (0.17-0.69) and specificity of 0.95 (0.85-0.98). 114 contained the interferon-stimulated gene IFI27, which was by itself the top-performing biomarker, originally 122 discovered in a paediatric cohort (30) to discriminate RSV infections from controls. 123

The candidate signatures evaluated in the present study are collectively associated with type 1 IFN responses, 124 which are a canonical feature of antiviral host defences. The importance of this response in SARS-CoV-2 infection 125 is highlighted by the association of severe COVID-19 with both of loss-of-function genetic variation in various 126 components of type 1 IFN pathways and with anti-type 1 IFN antibodies (31, 32). IFI27 is best characterised for 127 its functional role in type 1 IFN mediated apoptosis as a component of anti-tumour effects of IFNs (33). Differential 128 regulation of IFN inducible genes might explain why expression of IFI27 transcripts outperforms other type 1 IFN 129 signatures and merits investigation in future work to evaluate its significance in the anti-viral response. 130

A key feature of our study is that all participants self-declared as fit to work when attending study visits, including 131 at the time of their first positive SARS-CoV-2 PCR test, when most were asymptomatic. We also found detectable 132 expression of the signatures in blood transcriptomes collected at the study visit one week prior to virus PCR test 133 positivity among a subset of participants. Our data therefore demonstrate that measurable type 1 IFN-stimulated 134 responses to SARS-CoV-2 precede the onset of symptoms, and in some individuals may predate detectable viral 135 RNA on RT-PCR testing. We propose that novel diagnostic tests that detect transcripts (or associated protein 136 targets) from the top-performing candidate signatures could be valuable tools in the rapid detection and isolation 137 of individuals in the very earliest stages of pre-clinical infection. Importantly, these signatures also correlated with 138 viral load independently of symptoms, indicating that they have strong potential to identify the most infectious 139 individuals, critical to breaking chains of transmission. 140

A key strength of our study was the weekly longitudinal follow-up of study participants which enabled detailed 141 characterisation of the study cohort, including contemporaneous capture of blood RNA samples at the point of Committee, reference 20/SC/0149). All participants provided written informed consent. 159

We undertook a case-control study nested within our COVIDsortium health care worker cohort. Participant 161 screening, study design, sample collection, and sample processing have been described in detail previously (26-162 28) and the study is registered at ClinicalTrials.gov (NCT04318314). Briefly, healthcare workers were recruited at 163 Euroimmun anti-S1 spike protein and Roche anti-nucleocapsid protein throughout follow-up were included as 171 uninfected controls. 172

We performed a systematic literature search of peer-reviewed publications in order to identify concise blood 174 transcriptional signatures discovered or applied with a primary objective of diagnosis or assessment of severity of 175 viral infection from blood or PBMC samples. We searched Medline on 12/10/2020 using comprehensive MeSH and key word terms for "viral infection", "transcriptome", "biomarker" and "blood" (full search strategy shown in 177 Table S4 ). Additional studies were identified in reference lists and from expert consultation. Titles and abstracts 178 were initially screened by two independent reviewers; full-text review was performed for shortlisted articles to 179 determine eligibility and conflicts were resolved through discussion and arbitration by a third reviewer where 180 required. We focused on 'concise' signatures that might be more amenable to translation to diagnostic tests and 181 defined this as any signature discovered using a defined approach to feature selection to reduce the number of 182 constituent genes, as previously (36). We required that gene names that comprised the signature were publicly 183 available, along with the corresponding signature equation or model coefficients, and that the signature must be 184 validated in at least one independent test or validation set in order to prioritise signatures discovered from higher 185 quality studies. Where multiple signatures were discovered for the same intended purpose and from the same 186 discovery cohort, we included the signature with highest discrimination (as defined by the AUROC) in the validation 187 data, or the signature with fewest number of genes where accuracy was equivalent. 188

For each signature that met our eligibility criteria, we extracted constituent genes, modelling approaches and 189 coefficients to enable independent reconstruction of signature scores. Extraction was performed by a single 190 reviewer and was verified by a second reviewer. 

For each eligible signature, we reconstructed signature scores as per the original authors' descriptions. For logistic 201 and probit regression models, we calculated scores on the linear predictor scale by summing the expression of 202 each constituent gene multiplied by its coefficient. Scores for each signature were standardised to Z scores using 203 the mean and standard deviation among the uninfected control population. Scores that were designed to decrease 204 in viral infection were multiplied by −1 in order to ensure that higher scores should be associated with higher risk 205 of viral infection across all candidate signatures. 206

The primary outcome was the AUROC for discriminating participants with PCR-confirmed SARS-CoV-2 infection 207 during their first week of PCR positivity, from uninfected control samples. The secondary outcome was the AUROC 208 for discriminating participants with PCR-confirmed SARS-CoV-2 infections in the week prior to first PCR positivity, 209 from uninfected control samples. We calculated corresponding sensitivities and specificities for each signature for 210 the primary and secondary outcomes using pre-specified cut-offs based on two standard deviations above the 211 mean of the uninfected controls, as previously (36). In order to identify the subset of best performing signatures, 212

we performed pairwise DeLong tests to the signature with the highest AUROC for the primary outcome (or most 213 parsimonious in the event of equal performance), with adjustment for multiple testing using a Benjamini-Hochberg 214 correction (41). Signatures were considered to have statistically inferior accuracy to the best performing signature 215 if adjusted p<0.05. We also performed a sensitivity analysis for the primary outcome, excluding participants with 216 positive SARS-CoV-2 swabs who reported contemporaneous case-defining symptoms at the time of sampling. 217

Upstream analysis of transcriptional regulation of the constituent genes in the candidate signatures was performed 218 using Ingenuity Pathway Analysis (Qiagen, Venlo, The Netherlands) and visualized as network diagrams in Gephi 219 v0.9.2, depicting all statistically overrepresented molecules predicted to be upstream >2 target genes, as 220 previously (36). We evaluated pairwise Spearman rank and Jaccard indices between each candidate signature in 221 order to quantify correlations and proportions of intersecting genes between signatures. 222

The funder had no role in study design, data collection, data analysis, data interpretation, writing of the report, or 224 decision to submit for publication. The corresponding authors had full access to all the data in the study and had 225 final responsibility for the decision to submit for publication. 226 (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 20, 2021. ; https://doi.org/10.1101/2021.01.18.21250044 doi: medRxiv preprint Table S1 . Search strategy for systematic Medline search. 232 Table S2 . Validation metrics of whole-blood RNA signatures at week of first week of PCR-positivity. 233 Table S3 . Validation metrics of whole-blood RNA signatures at week prior to first week of PCR-positivity. 234 Table S4 . Baseline characteristics of the study cohort. 235 Table S5 . Full list of COVIDsortium investigators. Geometric mean of all genes ("influenza metasignature")

Five cohorts -children and adults with influenza; adults challenged with influenza; adults with bacterial pneumonia UK, USA and Australia Differential expression followed by leave-one-cohort-out strategy and filtering for heterogeneity of effect size, using genome-wide data Eight cohorts -children or adults with influenza or bacterial infection; adults challenged with influenza; adults vaccinated against influenza Influenza versus bacterial or other viral infection

Difference in geometric means between upregulated and downregulated genes ("Influenza paediatric signature score") Four cohorts -children with influenza-like illness USA Meta-analysis and leave-one-out strategy to identify common genes using genome-wide data Two cohortschildren or adults with influenza. 

Inborn errors of type I IFN immunity in patients with life-threatening COVID-19

Mitochondrial localization and pro-apoptotic effects of the interferon-inducible 368 protein ISG12a

Host Response Signatures RapidLy Discriminates Viral, Bacterial, and Non-infectious Etiologies of Illness

375 provided; we therefore included the two best performing single transcripts from the study in the current analysis, since they demonstrated similar performance to the 460 full model in the original publication

downregulated genes subtracted from the sum of upregulated genes. §Logistic and probit regression models were calculated on the linear predictor scale using model 462 coefficients from original publications. Abbreviations: RSV, respiratory syncytial virus. PAM, prediction analysis of microarrays. SVM, support vector machine

Least Absolute Shrinkage Selector Operator. RT-LAMP, Reverse Transcription Loop-mediated Isothermal Amplification. LCMV, lymphocytic choriomeningitis virus

Applications for access to the individual participant de-identified data (including data dictionaries) and samples 433 can be made to the access committee via an online application https://covid-consortium.com/application-for-434 samples/. Each application will be reviewed, with decisions to approve or reject an application for access made 435 on the basis of (i) accordance with participant consent and alignment to the study objectives (ii) evidence for the 436 capability of the applicant to undertake the specified research and (iii) availability of the requested samples. The 437 use of all samples and data will be limited to the approved application for access and stipulated in the material and 438 data transfer agreements between participating sites and investigators requesting access. 439

Open access to RNAseq data and associated essential metadata are available under accession no E-MTAB-441 10022 at ArrayExpress (https://www.ebi.ac.uk/arrayexpress/). 442